正在加载公司
Just reported
From Puma Biotechnology's results release of 2026年11月5日; its quarterly report has since been filed.
Actual
US$55.1M
+1.1% y/y
-2.6% q/q
Guided
US$57.5M
midpoint
Actual
US$0.11
-35% y/y
-31% q/q
Guided
—
No guide given
Actual
US$5.3M
-45% y/y
-30% q/q
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Puma Biotechnology is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.US$47.6BA+
EXELExelixis, Inc.US$16.8BA+
JAZZJazz Pharmaceuticals plcUS$15.5BA
TECHBIO-Techne CorpUS$11.4BA+
HALOHalozyme Therapeutics, Inc.US$11.4BA+Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026年10月21日CBGraded C, now B
MCKMckesson Corporation2026年11月4日BAGraded B, now A
CVSCVS Health Corp2026年11月4日BAGraded B, now A
EWEdwards Lifesciences Corporation2026年11月4日BAGraded B, now A
GEHCGE Healthcare Technologies Inc.2026年10月28日CAGraded C, now A基于 Puma Biotechnology, Inc. 自己向美国证券交易委员会（SEC）提交的申报文件。数字如实呈报，每股历史已重述到今天的股数口径。 这是对一门生意的描述——不是投资建议，也不是买卖任何证券的推荐。
公司指引：2026 财年营收 US$224M 至 US$227M — 同比下降 1.3%（上年同期 US$228.4M）
Grade B+
价格下方的色带显示每个日期的评级，仅依据当时已公开的文件计算。
显示 Puma Biotechnology, Inc. 评级历史 36 个季度中的 2 个。 其余 34 个可回溯到 2018年3月。
